Y. Shirayama et al., P-CHLOROPHENYLALANINE-REVERSIBLE REDUCTION OF SIGMA-BINDING SITES BY CHRONIC IMIPRAMINE TREATMENT IN RAT-BRAIN, European journal of pharmacology, 237(1), 1993, pp. 117-126
Repeated treatment with imipramine (10 mg/kg intraperitoneally (i.p.),
once daily for 14 days) caused a decrease in the B(max), without affe
cting the K(d) of [H-3]DTG (1,3-di-o-tolylguanidine) binding to the ha
loperidol-sensitive sigma sites in the striatum, hippocampus and cereb
ral cortex of the rat. A similar reduction was observed after chronic
administration of a selective serotonin uptake inhibitor, fluoxetine (
10 mg/kg i.p., twice daily for 14 days), but not of a selective norepi
nephrine uptake inhibitor, desipramine (10 mg/kg i.p., once daily for
14 days). Neither a single injection of imipramine (10 mg/kg i.p.) nor
addition of imipramine or fluoxetine into the binding assay medium mi
micked the changes in the maximal binding of brain sigma sites induced
by chronic treatment with these drugs. Finally, depletion of brain se
rotonin by means of repeated administration of p-chlorophenylalanine,
which produces inhibition of the amine synthesis, blocked the ability
of repeated imipramine treatment to reduce the maximal number of [H-3]
DTG binding sites in the striatum and hippocampus. The present results
suggest that cerebral serotonergic transmission may play a role in th
e regulation of cerebral sigma binding sites in the rat.